A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Active, not recruiting · NCT06305767 · Registry updated 2026-01-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, autosomal dominant Parkinson disease 4, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-01-13 | NCT06305767 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| ModernaTX, Inc. | 41 |
74 results · Page 1 of 3
Research sites
Swipe the table sideways for more columns.